Table 2.
Antiproliferative effect of T. terrestris standard extract (TtSE) and T. terrestris saponins-enriched extract (TtEE) extracts of T. terrestris and doxorubicin (DOX) against human cancer cell linesa
| Cell lines | GI50(µg/ml)b |
||
|---|---|---|---|
| DOX | TtEE | TtSE | |
| Glioma (U251) | 0.026 | 24.67 | 79.05 |
| Mama (MCF7) | <0.025 | 34.24 | 29.11 |
| Ovary (NCI-ADR-RES) | 0.16 | 26.26 | 56.01 |
| Kidney (786-O) | <0.025 | 2.91 | 30.63 |
| Lung (NCI-H460) | <0.025 | 27.24 | 77.40 |
| Prostate (PC-3) | 0.23 | 22.53 | 43.02 |
| Ovary (OVCAR-3) | 0.14 | 29.49 | 67.89 |
| Colon (HT-29) | 0.26 | 25.08 | 243.50 |
| Skin (line of non-tumor cells) (HaCat) | <0.025 | 21.02 | 33.17 |
a Assessed by the SRB assay.
b GI50 values represent the concentration (µg/ml) necessary for total inhibition of cancer cells proliferation. Dose range tested: 0.25–250 µg/ml of extracts and 0.025–25 µg/ml of doxorubicin.